Pluronic P105/F127 mixed micelles for the delivery of docetaxel against Taxol-resistant non-small cell lung cancer: Optimization and in vitro, in vivo evaluation

International Journal of Nanomedicine

Volumn 8, Issue , 2012, Pages 73-84

  Chen, Liangcen ^a   Sha, Xianyi ^a   Jiang, Xinyi ^a   Chen, Yanzuo ^a   Ren, Qiuyue ^a   Fang, Xiaoling ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Docetaxel; Multi drug resistance; Pluronic; Polymeric micelle

Indexed keywords

DOCETAXEL; PACLITAXEL; POLOXAMER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; CRITICAL MICELLE CONCENTRATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG RELEASE; DRUG RESISTANCE; DRUG RETENTION; DRUG SOLUBILITY; DRUG STABILITY; DRUG STORAGE; ENCAPSULATION; FREEZE DRYING; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; MALE; MEAN RESIDENCE TIME; MICELLE; MOUSE; NONHUMAN; PARTICLE SIZE; PROCESS OPTIMIZATION; RAT; SINGLE DRUG DOSE;

DOCETAXEL; MULTI-DRUG RESISTANCE; PLURONIC; POLYMERIC MICELLE;

ANIMALS; ANTINEOPLASTIC AGENTS; CALORIMETRY, DIFFERENTIAL SCANNING; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; DRUG STABILITY; HUMANS; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICELLES; NANOPARTICLES; PARTICLE SIZE; POLOXAMER; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; TAXOIDS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84872289754     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S38221     Document Type: Article

References (32)

1. Rowinsky EK. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu Rev Med. 1997;48: 353-374.
2. Lyseng-Williamson KA, Fenton C. Docetaxel: a review of its use in metastatic breast cancer. Drugs. 2005;65(17):2513-2531.
3. Michael A, Syrigos K, Pandha H. Prostate cancer chemotherapy in the era of targeted therapy. Prostate Cancer and Prostatic Dis. 2008;12(1): 13-16.
4. Cerny T, Kaplan S, Pavlidis N, et al. Docetaxel (Taxotere) is active in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group (ECTG). Br J Cancer. 1994;70(2):384-387.
5. Bissery MC, Nohynek G, Sanderink GJ, Lavelle F. Docetaxel (Taxotere): a review of preclinical and clinical experience. Part I: preclinical experience. Anticancer Drugs. 1995;6(3):339-355+363-368.
6. Gelderblom H, Verweij J, Nooter K, Sparreboom A, Cremophor EL. The drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer. 2001;37(13):1590-1598.
7. Kim TK, Kim IS, Yoo HH. Determination of docetaxel in rat plasma and its application in the comparative pharmacokinetics of Taxotere and SID530, a novel docetaxel formulation with hydroxypropyl-beta-cyclodextrin. Biomed Chromatogr. 2012. [Epub ahead of print.]
8. Zheng D, Li X, Xu H, Lu X, Hu Y, Fan W. Study on docetaxel-loaded nanoparticles with high antitumor efficacy against malignant melanoma. Acta Biochim Biophys Sin. 2009;41(7):578-587.
9. Alexopoulos A, Karamouzis MV, Stavrinides H, et al. Phase II study of pegylated liposomal doxorubicin (Caelyx®) and docetaxel as first-line treatment in metastatic breast cancer. Ann Oncol. 2004;15(6): 891-895.
10. Yin Y, Cui F, Mu C, Chung SJ, Shim C, Kim DD. Improved solubility of docetaxel using a microemulsion delivery system: formulation optimization and evaluation. Asian J Pharm Sci. 2009;4(6): 331-339.
11. Oerlemans C, Bult W, Bos M, Storm G, Nijsen JF, Hennink WE. Polymeric micelles in anticancer therapy: targeting, imaging and triggered release. Pharm Res. 2010;27(12):2569-2589.
12. Molnar J, Engi H, Hohmann J, et al. Reversal of multidrug resistance by natural substances from plants. Curr Top in Med Chem. 2010;10(17): 1757-1768.
13. Shirakawa K, Takara K, Tanigawara Y, et al. Interaction of Docetaxel ("Taxotere") with human p-glycoprotein. Jpn J Cancer Res. 1999;90(12):1380-1386.
14. Batrakova EV, Kabanov AV. Pluronic block copolymers: evolution of drug delivery concept from inert nanocarriers to biological response modifiers. J Control Release. 2008;130(2):98-106.
15. Alakhov V, Moskaleva E, Batrakova EV, Kabanov AV. Hypersensitization of multidrug resistant human ovarian carcinoma cells by pluronic P85 block copolymer. Bioconjug Chem. 1996;7(2):209-216.
16. Kabanov AV, Alakhov VY. Pluronic block copolymers in drug delivery: from micellar nanocontainers to biological response modifiers. Crit Rev Ther Drug Carrier Syst. 2002;19(1):1-72.
17. Wang Y, Li Y, Zhang L, Fang X. Pharmacokinetics and biodistribution of paclitaxel-loaded pluronic P105 polymeric micelles. Arch Pharm Res. 2008;31(4):530-538.
18. Zhang X, Jackson JK, Burt HM. Development of amphiphilic diblock copolymers as micellar carriers of taxol. Int J Pharm. 1996;132(1-2): 195-206.
19. Hu Y, Xie J, Tong YW, Wang C. Effect of PEG conformation and particle size on the cellular uptake efficiency of nanoparticles with the HepG2 cells. J Control Release. 2007;118(1):7-17.
20. Saxena V, Hussain MD. Poloxamer 407/TPGS mixed micelles for delivery of gambogic acid to breast and multidrug-resistant cancer. Int J Nanomedicine. 2012;7:713-721.
21. Yin Y, Cui F, Mu C, et al. Docetaxel microemulsion for enhanced oral bioavailability: preparation and in vitro and in vivo evaluation. J Control Release. 2009;140(2):86-94.
22. Qiu L, Bae Y. Polymer architecture and drug delivery. Pharm Res. 2006;23(1):1-30.
23. Oerlemans C, Bult W, Bos M, Storm G, Nijsen JF, Hennink WE. Polymeric micelles in anticancer therapy: targeting, imaging and triggered release. Pharm Res. 2010;27(12):2569-2589.
24. Butt AM, Amin MCIM, Katas H, Sarisuta N, Witoonsaridsilp W, Benjakul R. In vitro characterization of pluronic F127 and d-tocopheryl polyethylene glycol 1000 succinate mixed micelles as nanocarriers for targeted anticancer-drug delivery. J Nanomater. 2012; Article ID 916573.
25. Kim SY, Shin IG, Lee YM, Cho CS, Sung YK. Methoxy poly(ethylene glycol) and ∈-caprolactone amphiphilic block copolymeric micelle containing indomethacin II. Micelle formation and drug release behaviours. J Control Release. 1998;51(1):13-22.
26. Kabanov AV, Batrakova EV, Alakhov VY. Pluronic® block copolymers for overcoming drug resistance in cancer. Adv Drug Deliv Rev. 2002;54(5):759-779.
27. Reguiga MB, Bonhomme-Faivre L, Farinotti R. Bioavailability and tissular distribution of docetaxel, a P-glycoprotein substrate, are modified by interferon-α in rats. Journal of Pharmacy and Pharmacology. 2007;59(3):401-408.
28. Kabanov AV, Batrakova EV, Miller DW. Pluronic® block copolymers as modulators of drug efflux transporter activity in the blood-brain barrier. Adv Drug Deliv Rev. 2003;55(1):151-164.
29. Wang Y, Yu L, Han L, Sha X, Fang X. Difunctional pluronic copolymer micelles for paclitaxel delivery: synergistic effect of folate-mediated targeting and pluronic-mediated overcoming multidrug resistance in tumor cell lines. Int J Pharm. 2007;337(1-2):63-73.
30. Brannon-Peppas L, Blanchette JO. Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev. 2004;56(11):1649-1659.
31. Storm G, Belliot SO, Daemen T, Lasic DD. Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. Adv Drug Del Rev. 1995;17(1):31-48.
32. Maeda H, Bharate GY, Daruwalla J. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur J Pharm Biopharm. 2009;71(3):409-419.